Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893879 · ClinicalTrials.gov registry record · NA
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01893879: Clinical Trial NA study, sponsored by Stanford University.
NCT01893879 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01893879, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.
Primary Outcome
Participants were evaluated every 3 months up to one year post lymph node dissection
Interventions
- OTHER laboratory biomarker analysis
- DRUG placebo for study drug
- DRUG (RS)2-(3-benzoylphenyl)-propionic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-04 |
| Phase | NA |
Why NCT01893879 stopped before completion
NCT01893879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01893879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01893879 about?
NCT01893879 is a clinical study titled "Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema". This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.
What is the current status of trial NCT01893879?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2014-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01893879?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo for study drug (DRUG), (RS)2-(3-benzoylphenyl)-propionic acid (DRUG).
Who is sponsoring clinical trial NCT01893879?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01893879's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia